These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 7320990)

  • 1. Why not monitor our patients for adverse effects of drugs?
    Martys CR
    J R Coll Gen Pract; 1981 Jul; 31(228):435. PubMed ID: 7320990
    [No Abstract]   [Full Text] [Related]  

  • 2. Monitoring of adverse reactions to drugs in the United Kingdom.
    Inman WH
    Proc R Soc Med; 1970 Dec; 63(12):1302-4. PubMed ID: 5490790
    [No Abstract]   [Full Text] [Related]  

  • 3. Monitoring adverse effects of drugs in the community.
    Martys CR
    Practitioner; 1981 May; 225(1355):619-21. PubMed ID: 7291115
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug defect reporting.
    McBride D
    J R Coll Gen Pract; 1989 Mar; 39(320):90. PubMed ID: 2555501
    [No Abstract]   [Full Text] [Related]  

  • 5. Monitoring of drugs after marketing.
    J R Coll Gen Pract; 1983 Jul; 33(252):438-41. PubMed ID: 6887114
    [No Abstract]   [Full Text] [Related]  

  • 6. Discussion on control of new drugs.
    Practitioner; 1971 Apr; 206(234):546-50. PubMed ID: 4930721
    [No Abstract]   [Full Text] [Related]  

  • 7. Prospective monitoring for adverse reactions to drugs in general practice.
    Drury M; Hull FM
    Br Med J (Clin Res Ed); 1981 Nov; 283(6302):1305-7. PubMed ID: 6794834
    [No Abstract]   [Full Text] [Related]  

  • 8. Adverse drug reactions. A problem for drug regulatory agencies.
    Westerholm B
    Int J Clin Pharmacol; 1973 Apr; 7(2):183-9. PubMed ID: 4731286
    [No Abstract]   [Full Text] [Related]  

  • 9. Side-effects of drugs. Monitoring adverse reactions.
    Heenan A
    Nurs Times; 1989 Sep 27-Oct 3; 85(39):25-9. PubMed ID: 2587304
    [No Abstract]   [Full Text] [Related]  

  • 10. Adverse drug reactions: definition of the problem.
    Dunlop D
    Am J Epidemiol; 1971 Nov; 94(5):403-4. PubMed ID: 5120537
    [No Abstract]   [Full Text] [Related]  

  • 11. Advances in general practice.
    Scott RA
    Practitioner; 1965 Oct; 195(168):544-9. PubMed ID: 5831402
    [No Abstract]   [Full Text] [Related]  

  • 12. A field guide to the bleeding disorders for the general practitioner.
    Bevan DH
    Practitioner; 1982 Jan; 226(1363):25-32. PubMed ID: 7079221
    [No Abstract]   [Full Text] [Related]  

  • 13. Drugs monitor needs sharper teeth.
    Lesser F
    New Sci; 1983 Mar; 97(1349):729-32. PubMed ID: 11655525
    [No Abstract]   [Full Text] [Related]  

  • 14. Information on adverse reactions to drugs.
    Lancet; 1973 Feb; 1(7798):302-3. PubMed ID: 4119178
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pharmacovigilance in the framework of recording and control of drugs in the United Kingdom].
    Dunlop D
    Therapie; 1974; 29(6):799-804. PubMed ID: 4462229
    [No Abstract]   [Full Text] [Related]  

  • 16. Monitoring the adverse reactions to drugs and the discipline of therapeutic auditing.
    Wade OL
    Q J Med; 1971 Oct; 40(160):570-1. PubMed ID: 5157414
    [No Abstract]   [Full Text] [Related]  

  • 17. [International reporting of adverse effects of drugs].
    Offerhaus L
    Ned Tijdschr Geneeskd; 1992 Jul; 136(27):1294-5. PubMed ID: 1630516
    [No Abstract]   [Full Text] [Related]  

  • 18. Improving detection of adverse effects of marketed drugs.
    Klein DF; O'Brien CP
    JAMA; 2007 Jul; 298(3):333-4. PubMed ID: 17635895
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pharmacovigilance in 2004: why and how?].
    Lebrun-Vignes B
    Rev Med Interne; 2004 Jul; 25(7):487-9. PubMed ID: 15219365
    [No Abstract]   [Full Text] [Related]  

  • 20. Post-marketing surveillance.
    Lasagna L
    Triangle; 1980; 19(3-4):107-11. PubMed ID: 7013216
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.